Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Conditions: Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cholesterol, Elevated, Clinical Decision Support, Education
Interventions: Interruptive Reminder, Non-interruptive Reminder, No Reminder; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 38
States / cities: Tempe, Arizona • Los Angeles, California • Mission Viejo, California + 33 more

Conditions: Hypercholesterolemia, Vitamin D Deficiency
Interventions: Vitamin D (1000 or 2000 IU/day), Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions: Enhance health lifestyle changes and medication compliance; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Stanford, California

Conditions: Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions: Intervention Daily Avocado; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 25 Years and older
Enrollment: 1,008 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: LCQ908, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more

Conditions: Familial Hypercholesterolemia
Interventions: Cascade screening; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia, Familial, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Hypertriglyceridemia
Interventions: rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Hyperlipidemia
Interventions: LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Madison, Wisconsin

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, Statin, PF-04950615 (RN316), Satin; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 38
States / cities: Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more

Conditions: Hypercholesterolemia and Hyperlipidemia
Interventions: Ketogenic Diet, Control Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Lomitapide; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 97
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more

Conditions: Hyperlipidemia
Interventions: Evacetrapib, Atorvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 61
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more

Conditions: Hypertension, Type 2 Diabetes, Metabolic Syndrome, Smoking, High Cholesterol, PreDiabetes, Prehypertension
Interventions: Project WHADE: A Partner-Based Physical Activity Program for Women; Behavioral
Lead sponsor: Rowan University; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Glassboro, New Jersey

Conditions: Hypercholesterolemia, ASCVD
Interventions: Referral to Pharmacist-Driven Medication Management Program, Best-Practice Alert; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 95 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Hyperlipidemia, Hypertension, Pre-diabetes, Diabetes
Interventions: Lifestyle Intervention, Print Health Education; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Hypercholesterolemia
Interventions: Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 35 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Scottsdale, Arizona • Cincinnati, Ohio

Conditions: Homozygous Familial Hypercholesterolemic
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

Statin Reminders for Improving Prescribing in Primary Care

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Effects of Vitamin D on Lipids

Heart Disease on the Mend

Habitual Diet and Avocado Trial

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

Penn Family Screening for Familial Hypercholesterolemia

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Project WHADE: A Partner-Based Physical Activity Program for Women

Improving Lipid Optimization Quality and Treatment Options in ASCVD

Translating a Heart Disease Lifestyle Intervention Into the Community

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers